ClinicalTrials.gg
RecruitingNCT05216770Updated Dec 2, 2025

Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor

An Early Phase 1 interventional study of Brain imaging and Laryngeal sensory block with topical bupivacaine in Laryngeal Dystonia, Spasmodic Dysphonia and Tremor, sponsored by Massachusetts Eye and Ear Infirmary. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Massachusetts Eye and Ear Infirmary · Early Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 7 months later.
Phase
Early Phase 1
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The researchers will examine functional neural correlates that differentiate between laryngeal dystonia and voice tremor and contribute to disorder-specific pathophysiology using a cross-disciplinary approach of multimodal brain imaging.

Read the detailed description

Laryngeal dysphonia (LD) and Voice Tremor (VT) are neurological voice disorders that impair speech production. The characteristic feature of LD (i.e., occurring during speaking but not laughing or crying) and the lack of physical laryngeal abnormalities suggests that LD is likely a disorder affecting the task-specific control of phonation by the central nervous system (CNS). Similarly, VT is often observed without any clear peripheral laryngeal etiology, also suggesting a central origin but distinct from that affected in LD. The overall goal of this project is to characterize the common and distinct features of CNS pathophysiology in the neurological voice disorders, LD and VT. The act of speech is a dynamic process, including initial glottal movement, voice onset, and compensatory responses to sensory feedback fluctuations during sustained phonation. Identifying specific functional impairments in LD and VT requires a clear understanding of when in the process of phonation, as well as where in the CNS, aberrant activity occurs. Due to their poor temporal resolution, prior neuroimaging studies have not been able to address the question of when abnormal CNS activation occurs relative to specific phonation events. As a result, critical clues about the underlying etiologies in these disorders have likely been missed. A multimodal brain imaging will asses CNS abnormalities associated with LD and VT, specifically 1) Spatial and temporal CNS pathophysiology during speech and other vocal tasks; 2) Sensorimotor modulations on CNS pathophysiology; and 3) Motor learning and CNS pathophysiology. Future treatments for LD and VT can be developed by targeting CNS pathophysiological mechanisms identified in this project.

02

Conditions studied

  • Laryngeal Dystonia
  • Spasmodic Dysphonia
  • Tremor

Browse trials for

03

In context

Dysphonia

132 studies on the registry are indexed under Dysphonia; 38 are open to participants now.

This study's planned enrollment of 165 is above the median of 30 across 87 interventional studies indexed under Dysphonia.

Browse Dysphonia studies →

Lead sponsor

Massachusetts Eye and Ear Infirmary is the lead sponsor of 100 studies on the registry; 23 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females of diverse racial and ethnic background;
  2. Age 18-80 years;
  3. Native English speakers;
  4. Right-handed;
  5. Normal cognitive status;
  6. Patients will have laryngeal dystonia or voice tremor;
  7. Healthy controls will be healthy individuals without neurological, psychiatric or otolaryngological problems.

Exclusion criteria

Exclusion criteria:

  1. Subjects who are incapable of giving ;
  2. Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding. All women of will have a urine pregnancy test performed before MRI, which must be negative for participation in the imaging studies;
  3. Subjects with a past or present medical history of (a) neurological problems, such as stroke, movement disorders (other than specified LD and VT in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder, alcoholism, drug dependence; (c) laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis;
  4. Patients with any other form of dystonia;
  5. Patients who have dystonia symptoms at rest or have a presence of mirror dystonia;
  6. Patients who are not symptomatic due to treatment with botulinum toxin injections into the affected muscles. The duration of positive effects of botulinum toxin varies from patient to patient but lasts, on average, for 3-4 months. All patients will be evaluated to ensure that they are fully symptomatic and are at least 3 months post-injection before participation;
  7. To avoid the confounding effect of centrally acting drugs, all study participants will be questioned about any prescribed or over-the-counter medications as part of their initial screening. Those patients who receive medication(s) affecting the central nervous system will be excluded;
  8. Patients will be asked whether they have undergone any head or neck surgery, which resulted in changes in regional anatomy or innervation. Because brain or laryngeal surgery may potentially lead to brain structure and function re-organization, all patients with such a history will be excluded;
  9. Subjects who have certain tattoos and ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve) that cannot be removed for MRI studies.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
165 participants (estimated)

Study arms

  • Other
    Spatial and temporal CNS pathophysiology of laryngeal dystonia and voice tremor

    Simultaneous fMRI with EEG and MEG imaging will be used to examine neural dynamics during phonation.

    Other: Brain imaging

  • Active comparator
    Sensorimotor modulations of laryngeal dystonia and voice tremor with bupivacaine

    Topical laryngeal block (1 ml of 0.75% bupivacaine solution) will be used to modulate somatosensory feedback from the laryngeal mucosa during speech production and examine associated changes in brain activity.

    Drug: Laryngeal sensory block with topical bupivacaine

  • Other
    Motor learning and CNS pathophysiology of laryngeal dystonia and voice tremor

    Implicit learning of the production of motor sequences will be examined during simultaneous fMRI/EEG and MEG imaging. Sensorimotor adaptation of speech production during MEG imaging will be examined during perturbing pitch or formants of auditory feedback consistently during speech production and examining the behavioral and neural correlates of the resulting across-trial adaptation responses.

    Other: Brain imaging

  • Placebo comparator
    Placebo effects in laryngeal dystonia and voice tremor

    1 ml of saline placebo matching to 1 ml of 0.75% bupivacaine solution will be used for a comparison with the topical laryngeal block to modulate somatosensory feedback from the laryngeal mucosa during speech production and examine associated changes in brain activity.

  • Other
    Auditory feedback processing in laryngeal dystonia and voice tremor

    The role of auditory feedback processing on task-induced speech sensorimotor activity will be examined using MEG imaging during perturbing pitch or formants of auditory feedback, unpredictably during speech production, and examining the behavioral and neural correlates of the resulting within-trial compensation responses.

    Other: Brain imaging

Interventions

  • OtherBrain imaging

    Brain images will be conducted with function MRI, magnetoencephalography (MEG), and electroencephalography (EEG) to identify disorder-specific neural markers

  • DrugLaryngeal sensory block with topical bupivacaine

    Laryngeal sensory block with bupivacaine will be used to modulate sensory feedback from vocal fold mucosa and examine the impact of sensory feedback on abnormal neural activity in LD and VT

06

What researchers measure

Primary outcomes

  1. Functional MRI, MEG and EEG signal changes in laryngeal dystonia compared to voice tremor

    Qualitative analysis of brain regions with disorder-specific increases and decreases of spatial (functional MRI) and temporal (MEG and EEG) signals will be determined in patients with laryngeal dystonia compared to patients with voice tremor

    Time frame: 5 years

  2. Effects of sensorimotor brain modulation on voice function in laryngeal dystonia

    Quantitative measures of symptoms will be determined using Burk-Fahn-Marsden Dystonia Rating Scale where higher score means a worse outcome, following sensorimotor feedback modulation in patients with laryngeal dystonia

    Time frame: 5 years

  3. Effects of sensorimotor brain modulation on voice function in voice tremor

    Quantitative measures of symptoms will be determined using Fahn-Tolosa-Marin Rating Scale where higher score means a worse outcome, following sensorimotor feedback modulation in patients with voice tremor

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Massachusetts Eye and Ear and University of California San Francisco
    Boston, Massachusetts 02114, United States
    Recruiting
    • Kristina Simonyan, MD, PhD · ContactSimonyan_Lab@MEEI.HARVARD.EDU · 617-573-6016
    • Kristina Simonyan, MD, PhD · Principal investigator
    • Srikantan Nagarajan, PhD · Principal investigator
    • John Houde, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2022 (actual). Primary completion is estimated for Aug 2027, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2021
First posted
Feb 1, 2022
StartActual
Mar 24, 2022
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05216770
Responsible party
Kristina Simonyan (Professor of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear Infirmary) — Principal investigator
First posted
Feb 1, 2022
Start date
Mar 24, 2022
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Dec 2, 2025

Study contacts

Kristina Simonyan, MD, PhD
Contact
simonyan_lab@meei.harvard.edu
617-573-6016
Kristina Simonyan, MD, PhD
study director · Professor of Otolaryngology - Head and Neck Surgery

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion